Literature DB >> 18785315

Distribution of myeloid dendritic cells and plasmacytoid dendritic cells in the synovial tissues of rheumatoid arthritis.

Yuya Takakubo1, Michiaki Takagi, Kunihiko Maeda, Yasunobu Tamaki, Akiko Sasaki, Tamon Asano, Shigenobu Fukushima, Yoshiro Kiyoshige, Hiroshi Orui, Toshihiko Ogino, Mitsunori Yamakawa.   

Abstract

OBJECTIVE: To examine the precise tissue distribution of dendritic cells (DC) and indoleamine 2,3-dioxygenase (IDO)-expressing cells in synovial tissue and synovial fluid (SF) from patients with rheumatoid arthritis (RA) and osteoarthritis (OA).
METHODS: Synovial tissues from 30 patients with RA and 7 with OA were immunohistochemically stained for DC markers. The examined areas were classified into 5 categories based on pathobiological staging and histopathological grading systems. Myeloid DC (mDC) and plasmacytoid DC (pDC) were isolated using positive and negative magnetic sorting systems, respectively, from SF samples (7 patients with RA and 4 with OA) and synovial tissues (3 RA, 4 OA).
RESULTS: mDC were mainly observed in lymphoid aggregations. pDC were scattered around perivenular infiltration areas, and small and large lymphoid aggregations in RA. The mDC/pDC ratio increased significantly, with higher grading in RA SF tissues compared to OA synovial tissues (p<0.05). IDO-immunoreactivity was detected in pDC by serial sectioning and staining of RA synovial tissues.
CONCLUSION: Our results indicate that mature mDC play a central role in the RA inflammatory process. Although there were fewer pDC than mDC, the presence of IDO-positive pDC suggests a possible tolerance mechanism in RA synovial tissues. However, it is probably modest due to the marked inflammation in RA, in which mDC are dominant.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18785315

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  13 in total

1.  Midterm clinico-radiologic findings of an open label observation study of add-on tacrolimus with biologics or non-biologic DMARDs.

Authors:  Yuya Takakubo; Yasunobu Tamaki; Tomoyuki Hirayama; Kiyoshi Iwazaki; Suran Yang; Akiko Sasaki; Haruki Nakano; Yrjö T Konttinen; Michiaki Takagi
Journal:  Rheumatol Int       Date:  2011-11-08       Impact factor: 2.631

Review 2.  Plasmacytoid dendritic cells and immunotherapy in multiple sclerosis.

Authors:  Felipe von Glehn; Leonilda M Santos; Konstantin E Balashov
Journal:  Immunotherapy       Date:  2012-10       Impact factor: 4.196

Review 3.  Innate immunity and rheumatoid arthritis.

Authors:  Angelica Gierut; Harris Perlman; Richard M Pope
Journal:  Rheum Dis Clin North Am       Date:  2010-05       Impact factor: 2.670

4.  Essential requirement for IRF8 and SLC15A4 implicates plasmacytoid dendritic cells in the pathogenesis of lupus.

Authors:  Roberto Baccala; Rosana Gonzalez-Quintial; Amanda L Blasius; Ivo Rimann; Keiko Ozato; Dwight H Kono; Bruce Beutler; Argyrios N Theofilopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

5.  Inflammatory immune cell responses and Toll-like receptor expression in synovial tissues in rheumatoid arthritis patients treated with biologics or DMARDs.

Authors:  Yuya Takakubo; Yasunobu Tamaki; Tomoyuki Hirayama; Kiyoshi Iwazaki; Kan Sasaki; Akiko Sasaki; Hiroharu Ohki; Noe Takakubo; Yrjö T Konttinen; Michiaki Takagi
Journal:  Clin Rheumatol       Date:  2013-02-10       Impact factor: 2.980

6.  Alarmin human α defensin HNP1 activates plasmacytoid dendritic cells by triggering NF-κB and IRF1 signaling pathways.

Authors:  Fang Wang; Linan Qiao; Xing Lv; Anna Trivett; Rui Yang; Joost J Oppenheim; Ning Zhang
Journal:  Cytokine       Date:  2016-03-28       Impact factor: 3.861

Review 7.  Emerging immunotherapies for rheumatoid arthritis.

Authors:  Gary Reynolds; Faye A H Cooles; John D Isaacs; Catharien M U Hilkens
Journal:  Hum Vaccin Immunother       Date:  2014-02-17       Impact factor: 3.452

8.  The synovium in rheumatoid arthritis.

Authors:  Carol A Hitchon; Hani S El-Gabalawy
Journal:  Open Rheumatol J       Date:  2011-12-30

9.  The potential role of indoleamine 2,3 dioxygenase (IDO) as a predictive and therapeutic target for diabetes treatment: a mythical truth.

Authors:  Babak Baban; W Todd Penberthy; Mahmood S Mozaffari
Journal:  EPMA J       Date:  2010-03-19       Impact factor: 6.543

10.  Dendritic cells a double-edge sword in autoimmune responses.

Authors:  Giada Amodio; Silvia Gregori
Journal:  Front Immunol       Date:  2012-08-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.